Rationale: Collagen-and calcium-binding EGF domains 1 (CCBE1) has been associated with Hennekam syndrome, in which patients have lymphedema, lymphangiectasias, and other cardiovascular anomalies. Insight into the molecular role of CCBE1 is completely lacking, and mouse models for the disease do not exist.
T he vascular system consists of blood and lymphatic vessels, both of which are lined by endothelial cells (ECs). Lymphatic vessels play a key role in fluid homeostasis and are central to transport of macromolecules, immune system function, and intestinal lipid absorption. 1 Mice lacking lymphatic vessels due to loss-of-function mutations in vascular endothelial growth factor (VEGF)-C 2 or Prospero homeobox 1 (Prox1) 3 die in utero displaying severe edema. In humans, functional defects of lymphatic vessels result in a number of clinical conditions, such as lymphedema. 4 Lymphatic vessels are also implicated in metastatic dissemination, therefore playing an important role in tumor progression. 5 Recently, we identified the collagen-and calcium-binding EGF domains 1 (ccbe1) gene to be required for embryonic lymphangiogenesis in zebrafish. 6 Furthermore, collagen-and calcium-binding EGF domains 1 (CCBE1) was found to be mutated in a cohort of patients with Hennekam syndrome, 7 a rare disease that presents with lymphedema, lymphangiectasias, and other pathological features. 8 However, it has remained unclear in which stage of lymphatic development CCBE1 is required. Also, whether CCBE1 is an instructive or permissive factor has not been resolved.
Methods

Ccbe1 Mouse Allele
LacZ mice were generated by homologous recombination in embryonic stem cells with a lacZ cassette, replacing the first and second coding exons of Ccbe1 (Ccbe1 lacZ ). 9 human IgG1. Protein pellets (inert hydron, 0.2 mmϫ0.2 mm) containing 500 ng CCBE1 ⌬collagen -Fc (Genentech), 250 ng VEGF-C (Genentech), or both were inserted to the base of the corneal micropocket, approximately 1 mm from the limbus. After 10 days, corneas were harvested and processed as described. 10 An expanded Methods section is available in the Online Supplement.
Results
To unravel CCBE1 function during murine lymphatic development, we targeted the murine Ccbe1 locus by generating a lacZ allele (Ccbe1lacZ) ( Figure 1A ). During embryonic development, cells expressing Ccbe1 were found in multiple locations such as the brain, the mesothelium of the heart, and in close proximity to nascent blood and lymphatic vascular structures, with weak lacZ expression in some of these regions ( Figure 1B and Online Figure I ). In Ccbe1 Ϫ/Ϫ mice, patterning and density of blood vessels exhibited no gross abnormalities ( Figure 1C ). From E13.5 on, however, Ccbe1 Ϫ/Ϫ mice accumulated fluid and developed edema ( Figure 1D , arrows). All mutant mice died prenatally. Further analysis revealed that Ccbe1 Ϫ/Ϫ embryos lack all lymphatic vessels such as those found in skin ( Figure 1E , arrowheads). Thus, in mice, CCBE1 appears to be critically important for lymphangiogenesis but not for angiogenesis. Because early markers for lymphatic fate are missing in zebrafish, it has remained unclear whether lymphatic fates are established in the absence of ccbe1. Lyve-1 11 and Prox-1 3 , 2 early markers for LEC fate specification, were detected in E10.5 Ccbe1 Ϫ/Ϫ embryos (Figure 2A ), suggesting that LEC differentiation is unaffected in the absence of CCBE1. Normally, differentiated LECs bud and migrate away from the anterior cardinal veins between E10.5 and E12.0 and form lymph sacs between E11.5 and E13.5, which subsequently give rise to most of the lymphatic vasculature. We observed no lymph sacs, and only a few Prox-1 ϩ and Lyve-1 ϩ LECs were present in the wall of the cardinal vein in Ccbe1 Ϫ/Ϫ embryos, with even fewer LECs outside the cardinal vein ( Figure 2B , arrowhead), indicating an overall reduction in LECs at these stages and a primary defect before the formation of lymph sacs ( Figure 2C and 2D).
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These findings indicate that CCBE1 is essential for budding and/or migration of LECs from veins. Migration of LECs has previously been shown to be dependent on VEGF-C/Vegfr-3 signaling. 12 We analyzed LECs for Vegfr-3 tyrosine phosphorylation (pTYR/Vegfr-3) in situ, using a proximity ligation assay. 13 We quantified both the number of Lyve-1 ϩ cells and the number of pTYR/Vegfr-3 sites per Lyve-1 ϩ cell at E10.5 and E12.5 and confirmed a reduction in the number of Lyve-1 ϩ cells in Ccbe1 Ϫ/Ϫ embryos (Online Figure II) . However, at critical stages of LEC migration, levels of phosphorylated Vegfr-3 per Lyve-1 ϩ cell were unaltered, indicating that Vegfr-3 activation is not affected by the absence of CCBE1 and suggesting that CCBE1 may function independently of Vegfr-3 phosphorylation (Online Figure II) .
Because Vegfr-3 phosphorylation appeared normal in Ccbe1 Ϫ/Ϫ LECs and as suggested by the CCBE1 domain structure, we considered whether CCBE1 might be part of the extracellular matrix (ECM). Because we were unable to produce full-length CCBE1, and because previous 6, 7, 14 and new genetic evidence (Online Figure III) suggests that the majority of inactivating mutations is present in the EGF domains, we generated a truncated protein (CCBE1 ⌬collagen -Fc) consisting of the EGF and calcium-binding EGF domains of CCBE1 fused to an Fc domain, but lacking the collagen repeat domain (Online Figure IV) . CCBE1 ⌬collagen -Fc appeared to bind to collagen IV deposited by cultured HUVECs. Binding particularly occurred in cell-free areas (Online Figure IV) . We hence removed the cells before incubating the remaining ECM with either recombinant CCBE1 ⌬collagen -Fc, or human Fc-containing proteins Alk1-Fc 15 or anti-Nrp2 antibody 16 as negative controls. Collagen IV ( Figure 3A , arrows) but not laminin (data not shown) colocalized with CCBE1 ⌬collagen -Fc. Control proteins anti-Nrp2 ( Figure 3A , lower panels) and Alk1-Fc (data not shown) did not show binding to ECM components.
Because it is possible that the colocalization of CCBE1 ⌬collagen -Fc with ECM components is indirect (Colla- gen IV and CCBE1 might both bind a third, independent component of the ECM), we used a binary system where plates coated with a single ECM protein were incubated with CCBE1 ⌬collagen -Fc protein. In three independent experiments we found reproducible and weak interaction of CCBE1 ⌬collagen -Fc with Collagen I, Collagen IV and Collagen V ( Figure 3B) , with Collagen IV binding being variable. To fibronectin and laminin, CCBE1 ⌬collagen -Fc did not show binding. Strongest binding, however, was reproducibly observed with vitronectin in a dose-dependent manner ( Figure 3B ).
Our analysis of Ccbe1 Ϫ/Ϫ mice demonstrates that CCBE1 is important for LEC budding, migration, and sprouting. We hence tested whether exogenous CCBE1 has lymphangiogenic activity on its own or whether it may modify the lymphangiogenic activity of VEGF-C in vivo. CCBE1 ⌬collagen -Fc protein was used in a corneal micropocket assay and its effect compared with the effects of VEGF-C, a known inducer of lymphangiogenesis in the avascular cornea of mice. A single administration of CCBE1 ⌬collagen -Fc weakly but significantly induced growth of lymphatic vessels from the limbus region underneath the implanted pellets, whereas VEGF-C elicited a stronger response ( Figure 4A and 4C) . Strikingly, the lymphangiogenic response was strongly increased when CCBE1 ⌬collagen -Fc was administered together with VEGF-C, yielding a greater effect than previously observed with any other protein ( Figure 4A and 4C) . Of note, lymphatic vessels induced by the combined activity of CCBE1 and VEGF-C show a dramatically increased number of filopodial extensions in comparison to vessels induced by VEGF-C alone ( Figure 4B and 4D) .
Because the application of CCBE1 alone causes a weak response of lymphatic vessel outgrowth, this might be taken as an argument that CCBE1 is a molecule facilitating LEC migration. However, it has been shown that the infliction of a wound in the cornea attracts macrophages, which are known to produce high levels of VEGF-C. 17 Hence, it is conceivable that applying CCBE1 in this context is sufficient to elicit a Figure 3 . CCBE1 binds to components of the extracellular matrix. A, After removal of cells, CCBE1 ⌬collagen -Fc binds to ECM deposited by HUVECs, showing colocalization (orange) with collagen IV (red). Control Anti-Nrp2 (green) does not bind to Collagen IV (red). B, ELISA of CCBE1 ⌬collagen -Fc binding to various ECM components. CCBE1 ⌬collagen -Fc is able to bind different collagens, but most strongly binds to vitronectin in a dose-dependent manner. CCBE1 ⌬collagen -Fc does not bind to laminin and fibronectin. lymphangiogenic response, during which low levels of macrophage-produced VEGF-C are sufficient to stimulate LECs in the presence of exogenous CCBE1 in the environment. Further stimulation with exogenous VEGF-C ( Figure 4A and 4C) will then cause a considerably stronger response in this assay for adult lymphangiogenesis.
Discussion
We have shown that Ccbe1 is required for murine embryonic lymphangiogenesis, independent of Vegfr-3 phosphorylation. Given the embryonic lethal Ccbe1 Ϫ/Ϫ phenotype, mutations in CCBE1 in human Hennekam syndrome patients are likely to represent severe hypomorphic but not complete loss-of-function situations. Supporting the functional importance of the EGF domains, a truncated form of CCBE1 containing these domains is sufficient to induce a strong lymphangiogenic response in conjunction with VEGF-C in an in vivo assay.
Because CCBE1 is not required to alter the Vegfr-3 activation status, and because the effects of CCBE1 are less dramatic in the corneal micro pocket assay than the effects of VEGF-C, we favor a model in which CCBE1 is not an instructive factor but rather acts as an essentially required permissive factor. As such, CCBE1 is part of, or binds to, the ECM and modulates the effect of VEGF-C on lymphangiogenesis.
Novelty and Significance
What Is Known?
• Collagen and calcium-binding EGF domains 1 (ccbe1) is required for the development of lymphatic vessels during zebrafish embryonic development. • CCBE1 has been implicated with the human Hennekam syndrome, in which lymphatic and cardiovascular function is impaired.
What New Information Does This Article Contribute?
• We have generated a mouse model to study the expression and function of Ccbe1 during mammalian development. • Mice that lack Ccbe1 acquire severe edema and die prenatally. • Lymphatic endothelial cells are specified and present in Ccbe1 mutants, but these cells fail to migrate away from the cardinal vein and consequently lymphatic vessels do not develop. • Mutant lymphatic endothelial cells display apparently normal vascular endothelial growth factor receptor (Vegfr)-3 phosphorylation.
• Human recombinant CCBE1 protein binds to specific components of the extracellular matrix. • Human recombinant CCBE1 protein enhances VEGF-C driven lymphatic response in a corneal micropocket assay.
CCBE1 has been implicated in the human Hennekam syndrome, but a mouse model and insights into CCBE1 function are lacking. We show that CCBE1-deficient mice acquire severe edema, lack lymphatic vessels, and die prenatally. CCBE1 recombinant protein binds to components of the extracellular matrix and enhances the lymphangiogenic effect of VEGF-C in an in vivo assay. Our work demonstrates CCBE1 to be an essential factor for embryonic lymphangiogenesis and suggests CCBE1 modulation as a possible strategy for stimulating lymphatic vessel growth and improving clinical outcome of lymphatic-related diseases.
